EndoQuest Robotics partners with OMNIVISION

EndoQuest Robotics Inc. and OMNIVISION announced a partnership to integrate OMNIVISION's OCHFA CameraCubeChip into EndoQuest's Flexible Robotic System.

"We are excited to be able to incorporate OMNIVISION's market-leading sensor technology into the visualization component of our first of its kind platform," says Kurt Azarbarzin, CEO of EndoQuest Robotics. "We recognize that advanced imaging is essential to enhancing physician capabilities, especially inside the lumen of the gastrointestinal (GI) tract. OMNIVISION's newest technology is ideal for our Flexible Robotic System."

"We are pleased to integrate our OCHFA CameraCubeChip into the EndoQuest Robotics platform," says Tehzeeb Gunja, OMNIVISION's director of medical marketing. "The OCHFA CameraCubeChip is a high-performance visualization solution built with OMNIVISION's PureCelPlus-S pixel technology, with a small 1.008µm pixel size, in a 1/8" optical format; it features 720x720 resolution at 30 frames per second. The PureCelPlus-S technology enables high full-well capacity, zero blooming and lower power consumption for crisp, clear life-like images. The OCHFA CameraCubeChip comes in a compact 1.075mm x 1.075mm size, with a 5mm to 50mm focus range and 120° diagonal field-of-view that’s ideal for GI and other endoluminal procedures. It is a medical-grade, trusted component that undergoes comprehensive certification, qualification and testing, taking patient care and surgical visualization to the next level."

EndoQuest Robotics is focused on addressing the unmet needs in GI and other endoluminal surgeries by developing an innovative robotic system that offers precision, flexibility, and improved patient outcomes. The company's proprietary technology is designed to navigate and perform procedures within the body's natural orifices, allowing for the least invasive interventions and enhancing the capabilities of healthcare professionals. Since EndoQuest Robotics was founded, the company has collaborated extensively and will continue to do so with healthcare providers, researchers, and industry partners to advance the adoption of its revolutionary flexible endoluminal robotic system, ultimately improving patient outcomes and redefining a new standard of care in minimally invasive surgery.

EndoQuest's Flexible Robotic System is under development, has not been cleared by the FDA and is not for commercial sale in the United States.